Literature DB >> 3264311

Suppression of lymphokine-activated killer induction by neutrophils.

H Y Shau1, A Kim.   

Abstract

Peripheral blood polymorphonuclear neutrophils (PMN) suppressed the induction of PBL lymphokine-activated killer (LAK) function by rIL-2 in vitro. The suppression depended on the concentration of PMN in the IL-2 culture, and required intact PMN. However, PMN did not require treatment with immunoregulators such as IL-2, LPS, or TNF to express the suppressive activity, and no direct contact with PBL was needed for the suppression. Addition of anti-TNF antibodies had no effect on the suppression, suggesting that no endogenous TNF in the culture was involved in the suppression. PMN did not inhibit LAK function by preventing utilization of IL-2 by PBL or by selective depletion of NKH-1+ cells which constitute the majority of LAK precursors in PBL. The suppression was reversed by superoxide dismutase but not by catalase, suggesting that superoxide anion, not hydrogen peroxide, was involved in the suppression. No other suppressive factor was detectable in PMN culture supernates. Our results of PMN regulating LAK induction in vitro suggest that PMN may have a role in determining the outcome of immunotherapy with IL-2 in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264311

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Effects of tumor-necrosis-factor-activated neutrophils on tumor cell survival.

Authors:  H Shau
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  Induction of activated killer cells from human lymphocytes by medullasin (a serine protease in bone marrow cells).

Authors:  Y Aoki; T Hase; K Oshimi; K Suzuki
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

3.  Effects of anticoagulant, serum, and temperature on the natural killer activity of human peripheral blood mononuclear cells stored overnight.

Authors:  B K Son; R L Roberts; B J Ank; E R Stiehm
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

4.  Elevated preoperative neutrophil-to-lymphocytes ratio predicts poor prognosis after esophagectomy in T1 esophageal cancer.

Authors:  Kenichi Nakamura; Naoya Yoshida; Yoshifumi Baba; Keisuke Kosumi; Tomoyuki Uchihara; Yuki Kiyozumi; Mayuko Ohuchi; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Masayuki Watanabe; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2017-01-17       Impact factor: 3.402

5.  Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients.

Authors:  Keisuke Kosumi; Yoshifumi Baba; Takatsugu Ishimoto; Kazuto Harada; Kenichi Nakamura; Mayuko Ohuchi; Yuki Kiyozumi; Daisuke Izumi; Ryuma Tokunaga; Katsunobu Taki; Takaaki Higashi; Tatsunori Miyata; Junji Kurashige; Yukiharu Hiyoshi; Shiro Iwagami; Yasuo Sakamoto; Yuji Miyamoto; Naoya Yoshida; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2015-06-03       Impact factor: 2.549

6.  Pretreatment neutrophil/lymphocyte ratio but not platelet/lymphocyte ratio has a prognostic impact in multiple myeloma.

Authors:  Yanjie Li; Hujun Li; Wenjing Li; Lijin Wang; Zhiling Yan; Yao Yao; Ruosi Yao; Kailin Xu; Zhenyu Li
Journal:  J Clin Lab Anal       Date:  2016-12-07       Impact factor: 2.352

7.  Soluble factors produced by macrophages/monocytes inhibit lymphokine-activated killer activity in rat splenocyte cultures.

Authors:  P J Kuppen; A M Eggermont; R B Quak; A Marinelli; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

8.  Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma.

Authors:  Vidal M Arroyo; Philip J Lupo; Michael E Scheurer; Surya P Rednam; Jeffrey Murray; M Fatih Okcu; Murali M Chintagumpala; Austin L Brown
Journal:  Cancer Epidemiol       Date:  2019-01-29       Impact factor: 2.984

9.  The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis.

Authors:  Shouyu Wang; Zhen Zhang; Fengqi Fang; Xue Gao; Wei Sun; Huanran Liu
Journal:  Oncol Lett       Date:  2011-05-13       Impact factor: 2.967

10.  Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

Authors:  A Schomburg; H Kirchner; J Atzpodien
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.